S.CollegeLewisCollegeIICollegeJohn Wiley & Sons, Ltd.Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyNathisuwen S., Burgess D.S., and Lewis J.S. Extended spectrum beta- lactamases: Epidemiology, detection and treatment. Pharmacotherapy, 2001; 21: 920 - 928....
Chaudhury U, Aggarwal R; Extended spectrum beta-lactamases (ESBL)-An emerging threat to clinical therapeutics. Indian J Med Microbiol., 2004; 22(2): 75-80.Chaudhary U, Aggarwal R. Extended spectrum-lactamases (ESBLs) - an emerging threat to clinical therapeutics. Indian J Med Microbiol 2004...
The production of extended-spectrum beta-lactamases (ESBL) confers resistance to the majority of the commonly used beta-lactam antimicrobials, including 3rd generation cephalosporins, but excluding beta-lactamase inhibitors (e.g. clavulanic acid). ESBLs confer resistance to beta-lactam antibiotics via ...
前言一個抗生素的研發成功耗時約20年,但細菌只需區區數年便演化出對抗策略。本文之廣效性乙內醯胺酉每(Extended-spectrumβ-lactamases;ESBL)的產生就是細菌..
6) Extended-spectrumβ-lactamases-producing Escherichia coli (ESBLs-EC) 产超广谱β-内酰胺酶的大肠杆菌(ESBLs-EC)补充资料:β-内酰胺酶抑制剂 分子式:C8H8KNO5分子量:暂无CAS号:61177-45-5性质:暂无制备方法:暂无用途:β-内酰胺酶抑制剂。 说明:补充资料仅用于学习参考,请勿用于其它任何用途。
Extended-spectrum beta-lactamases (ESBLs) are a rapidly evolving group of beta-lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam yet are inhibited by clavulanic acid. Typically, they derive from genes for TEM-1, TEM-2, or SHV-1 by mutations that alter...
3)ESBLs超广谱酶β内酰胺酶(ESBLs) 4)E.coli producing ESBLs产超广谱β-内酰胺酶大肠埃希菌 英文短句/例句 1.Clinical Surveys of E.coli. Producing Extended-Spectrum beta-lactamase产超广谱β-内酰胺酶大肠埃希菌的临床调查 2.Test of extended spectrum β-lactamases with colon bacillus产超广谱β-内酰...
Prevalence of Extended Spectrum Beta Lactamases (ESBL) producing Escherichia coli and Klebsiella Pneumoniae in Tuberculosis patients n Kano, Nigeria. Bajopas., 4(2):182-185.Yusuf I, Arzai AH, Umar A, Magaji N, Salisu N, Tukur A, Hamid KM, Haruna M (2011) Prevalence of Extended Spectrum ...
2) ESBLS 超广谱β-内酰氨酶 1. The double-disk synergy tests were carried out with extended spectrum β-lactamases (ESBLS). 结果从2001~2005年检出的大肠埃希菌对青霉素类药物耐药率最高,对亚胺培南耐药率最低,氨基糖苷类和第三代头孢菌素药物具有较好的体外抗菌活性,大肠埃希菌超广谱β-内酰氨酶(...
The treatment of Shigella infections has become a major challenge due to the emergence of multidrug-resistant Shigella. There is however insufficient knowledge regarding the molecular epidemiology of Shigella strains producing beta-lactamases in Africa.